A-2025-Update-on-the-GLP1-Landscape

A 2025 Update on the GLP-1 Landscape

05/01/2025 Written by: Jim Hartz and Virak Nhek

Prescription-level weight loss drugs are making waves across the country, changing health norms, social norms, and economic models for healthcare spend. Often referred to as GLP-1s (Glucagon-like Peptide-1), these drugs have not only expanded utilization amongst type-2 diabetics but have more recently become a widely accepted approach for weight loss. The number of plans expanding coverage of GLP-1’s to include weight loss has nearly doubled in the past several years, currently representing approximately 15% of self-insured plans.

For employer-sponsored health plans a script can translate to an annual expense of up to $10k per utilizer. As these drugs become more popular, employers need to consider how this trend will affect their health plans and find their desired balance between the benefits these medications offer to patients, and the financial impact of coverage.

We have reviewed, and followed closely, the studies expanding the indications for GLP-1s to include kidney disease, cardiovascular disease, and even sleep apnea. While research is still ongoing, once approved, these new indications will increase the number of utilizers.

AssuredPartners recently went back and analyzed trends across one of our data sets of self-insured employers (over 3.7M member months) to better understand the increased utilization of GLP-1s from 2019 through 2024. These results showed notable increases in the PMPM costs of the top 6 GLP-1 drugs. Please see the attached exhibit: The total PMPM costs of these medications increased from $1.43 in 2019 to $24.59 in 2024 - a compounded annual rate of 77% per year. The primary drivers of this increase were Ozempic, Wegovy, and Mounjaro.

 A-2025-Update-on-the-GLP1-Landscape

*Note: Approximately 40% of employer groups covered GLP-1s for anti-obesity within this data set.

Contact us today for individualized GLP-1 strategy guidance for your organization.

Contact Us!

Can Employer’s manage the expanding utilization?

Employers who intend to expand access for weight loss may want to explore comprehensive solutions, such as third-party wellness programs that include behavioral health support and nutritional advice that aid in supporting members health goals. New programs are coming to market that will guide members through how to incorporate anti-obesity agents to effectively monitor results and outcomes. These programs are designed to increase member engagement, which may include a health coach or nutritionist, increasing the likelihood of more sustainable outcomes.

Where do we go from here?

As the impact of GLP-1s continues to evolve, employers should collaborate with their consultants to formulate a comprehensive coverage strategy and closely monitor its effects on their health plans. Approaches include implementing coverage with recommended safeguards, such as prior authorization, or restricting coverage to anti-diabetic/anti-obesity agents based solely on medical necessity. So far, the medical community has not embraced safeguards or controls such as weight loss thresholds, limited durations, or target BMI, to limit or manage access.

We expect the majority of employer sponsored plans to continue with restricted access for weight loss, for now.

Be sure to sign up for our newsletters, as we will be releasing a more comprehensive review of GLP-1 trends in the coming weeks.

The-Importance-of-PSA-Testing-and-Mens-Healthcare-Screenings
The Importance of PSA Testing and Men’s Healthcare Screenings
Employee Benefits04/22/2025

As a result of the COVID-19 pandemic, many employers are seeing an increase in delayed detection of cancer and chronic condition diagnoses. In response to this trend, employers are looking for ways...

Better-Understand-Your-Plan-Spend-with-Healthcare-Analytics
Better Understand Your Plan Spend with Healthcare Analytics
Employee Benefits04/15/2025

The enhanced use of healthcare analytics is revolutionizing how employers are able to interpret data about their population that can aid in the successful evaluation and development of their employee...

New-CHIP-Model-Notice-Released-by-DOL-for-2025
New CHIP Model Notice Released by DOL for 2025
Employee Benefits04/09/2025

A new Children’s Health Insurance Plan (CHIP) Notice has just been issued by the Department of Labor (DOL), reflecting updated information which brings it current to March 17, 2025. For background,...